Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Categories: @vaccine-makers   

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Website: jnj.com


  • Good financial results growth rate 90.5% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (10.7%)
  • Dividend yield for the last twelve months 3.3%
  • Free cash flow yield -1.0% (LTM)
  • Share price is 8.0% higher than minimum and 15.8% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (12.3x vs
    )
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: JNJ
Share price, USD:  (+0.1%)153.41
year average price 155.56  


year start price 146.42 2024-06-06

min close price 142.06 2025-01-10

max close price 167.70 2025-03-10

current price 153.29 2025-06-05
Common stocks: 2 631 399 832

Dividend Yield:  3.3%
FCF Yield LTM: -1.0%
EV / LTM EBITDA: 12.3x
EV / EBITDA annualized: 6.8x
Last revenue growth (y/y):  +2.4%
Last growth of EBITDA (y/y):  +178.6%
Historical revenue growth:  +0.3%
Historical growth of EBITDA:  +21.1%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 403 683
Net Debt ($m): 13 471
EV (Enterprise Value): 417 154
EBITDA LTM ($m): 33 900
EV / LTM EBITDA: 12.3x
Price to Book: 5.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-06-03zacks.com

Johnson & Johnson (JNJ) Stock Dips While Market Gains: Key Facts

2025-06-02youtube.com

'No more tears': Author Gardiner Harris on J&J's controversies over the years

2025-05-30youtube.com

J&J CEO Joaquin Duato on cancer treatments, M&A outlook and 'most favored nation' policy

2025-05-30247wallst.com

These 2 Dividend Stocks Have Grown Dividends For 50 Consecutive Years. Can That Streak Continue?

2025-05-28businesswire.com

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

2025-05-28seekingalpha.com

Johnson & Johnson (JNJ) Presents at the Bernstein's 41st Annual Strategic Decisions Conference (Transcript)

2025-05-22zacks.com

Johnson & Johnson (JNJ) Declines More Than Market: Some Information for Investors

2025-05-22zacks.com

JNJ Down 6% in 3 Months: How to Play the Stock Amid Various Challenges

2025-05-21businesswire.com

Johnson & Johnson to Participate in the Bernstein's 41st Annual Strategic Decisions Conference

2025-05-20seekingalpha.com

Johnson & Johnson (JNJ) RBC Capital Markets Global Healthcare Conference
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data